Skip to main content

Table 4 Rates of physician’s preferencea (mITT/ITT/PP population)

From: Final results from IMPROVE: a randomized, controlled, open-label, two-arm, cross-over phase IV study to determine patients’ preference for everolimus in combination with exemestane or capecitabine in combination with bevacizumab in advanced HR-positive, HER2-negative breast cancer

mITTArm A (N = 5)Arm B (N = 8)Total (N = 13)
n (%)95%-CIn (%)95%-CIn (%)95%-CI
Cap+Bev3 (60.0%)[14.7, 94.7]3 (37.5%)[8.5, 75.5]6 (46.2%)[19.2, 74.9]
Eve+Exe2 (40.0%)[5.3, 85.3]2 (25.0%)[3.2, 65.1]4 (30.8%)[9.1, 61.4]
I cannot decide0 3 (37.5%)[8.5, 75.5]3 (23.1%)[5.0, 53.8]
ITTArm A (N = 39)Arm B (N = 38)Total (N = 77)
n (%)95%-CIn (%)95%-CIn (%)95%-CI
Cap+Bev10 (25.6%)[13.0, 42.1]10 (26.3%)[13.4, 43.1]20 (26.0%)[16.6, 37.2]
Eve+Exe5 (12.8%)[4.3, 27.4]5 (13.2%)[4.4, 28.1]10 (13.0%)[6.4, 22.6]
I cannot decide2 (5.1%)[0.6, 17.3]4 (10.5%)[2.9, 24.8]6 (7.8%)[2.9, 16.2]
PPArm A (N = 13)Arm B (N = 18)Total (N = 31)
n (%)95%-CIn (%)95%-CIn (%)95%-CI
Cap+Bev8 (61.5%)[31.6, 86.1]10 (55.6%)[30.8, 78.5]18 (58.1%)[39.1, 75.5]
Eve+Exe5 (38.5%)[13.9, 68.4]5 (27.8%)[9.7, 53.5]10 (32.3%)[16.7, 51.4]
I cannot decide0 3 (16.7%)[3.6, 41.4]3 (9.7%)[2.0, 25.8]
  1. aPhysician’s preference was evaluated after 12 weeks of second-line treatment, assessed by the Physician Preference Questionnaire. Confidence interval was calculated using the Clopper-Pearson formula. Discrepancies between the sum of patients in the ITT population and the total n reported are due to patients, who did not cross over to the second-line therapy. mITT = modified ITT; ITT = intent-to-treat; PP = per-protocol; CI = confidence interval